Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10329093" target="_blank" >RIV/00179906:_____/16:10329093 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/16:10329093

Result on the web

<a href="http://dx.doi.org/10.1007/s00428-016-2000-3" target="_blank" >http://dx.doi.org/10.1007/s00428-016-2000-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00428-016-2000-3" target="_blank" >10.1007/s00428-016-2000-3</a>

Result language

angličtina

Original language name

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Original language description

Rearrangements of the ROS1 gene occur in 1-2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC. Consequently, focus on ROS1 testing is growing. Most laboratories currently rely on fluorescence in situ hybridisation (FISH) assays using a dual-colour break-apart probe to detect ROS1 rearrangements. Given the rarity of these rearrangements in NSCLC, detection of elevated ROS1 protein levels by immunohistochemistry may provide cost-effective screening prior to confirmatory FISH testing. Non-in situ testing approaches also hold potential as stand-alone methods or complementary tests, including multiplex real-time PCR assays and next-generation sequencing (NGS) platforms which include commercial test kits covering a range of fusion genes. In order to ensure high-quality biomarker testing, appropriate tissue handling, adequate control materials and participation in external quality assessment programmes are essential, irrespective of the testing technique employed. ROS1 testing is often only considered after negative tests for EGFR mutation and ALK gene rearrangement, based on the assumption that these oncogenic driver events tend to be exclusive. However, as the use of ROS1 inhibitors becomes routine, accurate and timely detection of ROS1 gene rearrangements will be critical for the optimal treatment of patients with NSCLC. As NGS techniques are introduced into routine diagnostic practice, ROS1 fusion gene testing will be provided as part of the initial testing package.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FP - Other medical fields

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Virchows Archiv

ISSN

0945-6317

e-ISSN

—

Volume of the periodical

469

Issue of the periodical within the volume

5

Country of publishing house

DE - GERMANY

Number of pages

15

Pages from-to

489-503

UT code for WoS article

000387226000002

EID of the result in the Scopus database

2-s2.0-84982273316